GlaxoSmithKline: Jemperli Plus Chemotherapy Approved in the US as the First New Frontline Treatment Option in Decades for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
August 01, 2023
August 01, 2023
LONDON, England, Aug. 1 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on July 31, 2023:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an . . .
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an . . .